The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $2.27 in the prior trading day, ProQR Therapeutics N.V (NASDAQ: PRQR) closed at $2.14, down -5.73%. In other words, the price has decreased by -$5.73 from its previous closing price. On the day, 0.55 million shares were traded. PRQR stock price reached its highest trading level at $2.3294 during the session, while it also had its lowest trading level at $2.12.
Ratios:
Our goal is to gain a better understanding of PRQR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.36. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.18.
On April 29, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $5.
Citigroup Upgraded its Neutral to Buy on March 10, 2025, while the target price for the stock was maintained at $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRQR now has a Market Capitalization of 225438720 and an Enterprise Value of 135046704. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.21 while its Price-to-Book (P/B) ratio in mrq is 3.36. Its current Enterprise Value per Revenue stands at 8.402 whereas that against EBITDA is -3.097.
Stock Price History:
The Beta on a monthly basis for PRQR is 0.18, which has changed by -0.12355214 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, PRQR has reached a high of $3.10, while it has fallen to a 52-week low of $1.07. The 50-Day Moving Average of the stock is -10.10%, while the 200-Day Moving Average is calculated to be 6.15%.
Shares Statistics:
The stock has traded on average 523.91K shares per day over the past 3-months and 806440 shares per day over the last 10 days, according to various share statistics. A total of 105.35M shares are outstanding, with a floating share count of 70.02M. Insiders hold about 33.45% of the company’s shares, while institutions hold 35.10% stake in the company. Shares short for PRQR as of 1764288000 were 1062666 with a Short Ratio of 2.03, compared to 1761868800 on 775919. Therefore, it implies a Short% of Shares Outstanding of 1062666 and a Short% of Float of 1.4199998999999999.
Earnings Estimates
The stock of ProQR Therapeutics N.V (PRQR) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.1 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.44 and -$0.52 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.62, with 8.0 analysts recommending between -$0.43 and -$0.82.
Revenue Estimates
5 analysts predict $6.09M in revenue for. The current quarter. It ranges from a high estimate of $11.99M to a low estimate of $2.78M. As of. The current estimate, ProQR Therapeutics N.V’s year-ago sales were $4.85MFor the next quarter, 5 analysts are estimating revenue of $5.53M. There is a high estimate of $8.58M for the next quarter, whereas the lowest estimate is $2.78M.
A total of 6 analysts have provided revenue estimates for PRQR’s current fiscal year. The highest revenue estimate was $25.46M, while the lowest revenue estimate was $13.22M, resulting in an average revenue estimate of $18.48M. In the same quarter a year ago, actual revenue was $21.34MBased on 5 analysts’ estimates, the company’s revenue will be $20.05M in the next fiscal year. The high estimate is $25.32M and the low estimate is $11M.
